Roger Susi Sells 5,000 Shares of iRadimed (NASDAQ:IRMD) Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $100.38, for a total value of $501,900.00. Following the completion of the transaction, the chief executive officer directly owned 2,235,000 shares of the company’s stock, valued at $224,349,300. This trade represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

iRadimed Stock Performance

Shares of IRMD stock opened at $98.74 on Friday. The firm has a market capitalization of $1.26 billion, a PE ratio of 56.42 and a beta of 1.12. iRadimed Corporation has a 1 year low of $47.48 and a 1 year high of $107.90. The stock has a fifty day moving average of $100.46 and a two-hundred day moving average of $90.28.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.05. The business had revenue of $22.69 million for the quarter, compared to analysts’ expectations of $21.60 million. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Equities research analysts predict that iRadimed Corporation will post 1.66 earnings per share for the current fiscal year.

iRadimed Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Monday, February 23rd were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Monday, February 23rd. This is a positive change from iRadimed’s previous quarterly dividend of $0.17. This represents a $0.80 annualized dividend and a yield of 0.8%. iRadimed’s dividend payout ratio is presently 45.71%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Lake Street Capital restated a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a report on Wednesday, February 11th. Roth Mkm reissued a “buy” rating and issued a $120.00 price target on shares of iRadimed in a report on Tuesday, February 10th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, iRadimed presently has an average rating of “Moderate Buy” and a consensus price target of $120.00.

Institutional Trading of iRadimed

Institutional investors and hedge funds have recently bought and sold shares of the stock. CWM LLC boosted its holdings in shares of iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 211 shares during the period. Quarry LP purchased a new position in iRadimed during the 3rd quarter worth approximately $40,000. Farther Finance Advisors LLC raised its stake in iRadimed by 827.1% during the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 397 shares during the period. Tower Research Capital LLC TRC raised its stake in iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 495 shares during the period. Finally, State of Alaska Department of Revenue purchased a new stake in shares of iRadimed in the third quarter valued at $47,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.